Skip to main content

Home/ Cancer/ Group items tagged adjunctive

Rss Feed Group items tagged

Matti Narkia

Should Vitamin C Be Used as an Adjunctive Treatment in Cancer - 0 views

  •  
    Should Vitamin C Be Used as an Adjunctive\nTreatment in Cancer. \nJack Challem. \nMedical Journal Watch 2009 Feb.
Matti Narkia

Inhibition of suppressor T lymphocytes (Ts) by cimetidine. - J Immunol. 1987 May - 0 views

  •  
    Inhibition of suppressor T lymphocytes (Ts) by cimetidine. Sahasrabudhe DM, McCune CS, O'Donnell RW, Henshaw EC. J Immunol. 1987 May 1;138(9):2760-3. PMID: 2952721 Cyclophosphamide (CY) is the most extensively studied inhibitor of suppressor T lymphocyte (Ts) function. However, repeated administration of CY can abrogate sensitization. Therefore, we were interested in identifying noncytotoxic inhibitors of Ts function as adjuncts in the immunotherapy of Ts-inducing murine tumors. The effect of cimetidine (a histamine type 2 receptor antagonist) and diphenhydramine (a histamine type 1 receptor antagonist) on the Ts mediating tolerance to 2,4-dinitrofluorobenzene was studied. We report our data regarding the specific inhibition of Ts by cimetidine.
Matti Narkia

Coriolus versicolor and cancer (June 2003) - 0 views

  •  
    Attached please find the final draft of Dr. Kenyon's non-controlled observational study on the use of Coriolus versicolor (non-extracted) in 30 solid tumour cancer patients. The final report will be published in the February edition of Mycology News 7. The patients were Stage III and Stage IV patients in which chemotherapy and radiotherapy were not considered successful. Below please find a synopsis of patient type.
Matti Narkia

Mistletoe, a new branch of cancer treatment | Mail Online - 1 views

  •  
    "For years, it's been the perfect excuse for secret admirers to steal a kiss with the object of their desire. But research suggests mistletoe could do much more than just ignite Christmas passions. Scientists have found an extract of the plant could help to fight bowel cancer, which affects 37,500 a year in the UK. Patients who had the mistletoe treatment regularly injected into their blood had fewer side-effects from toxic chemotherapy and radiotherapy and survived longer than those who did not. The extract is thought to help the body's immune system fight tumours and speed up the disposal of toxic 'debris' left by chemotherapy. Researchers led by Professor Kurt Zanker from the German Institute of Immunology and Experimental Oncology, concluded: 'The results suggest convincing evidence that there is a significant benefit from treatment with mistletoe extract.' The scientists treated 429 cancer patients with the mistletoe jab and compared them with 375 receiving conventional care. The results, published in the journal of The Society For Integrative Oncology, showed only 19 per cent of those in the mistletoe group suffered side-effects from toxic treatments, compared to 48 per cent in the other group. They were also 32 per cent more likely to still be alive five years after starting therapy."
1 - 4 of 4
Showing 20 items per page